Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension

Journal of Heart and Lung Transplantation

Volumn 29, Issue 2, 2010, Pages 150-156

  Jing, Zhi Cheng ^a   Strange, Geoff ^b   Zhu, Xian Yang ^c   Zhou, Da Xin ^d   Shen, Jie Yan ^e   Gu, Hong ^f   Yang, Zhen Kun ^g   Pan, Xin ^g   Xiang, Mei Xiang ^h   Yao, Hua ⁱ   Zhao, Dong Bao ^j   Dalton, Brad S ^k   Zhang, Zhuo Li ^l   Wang, Yong ^m   Cheng, Xian Sheng ⁿ   Yang, Yue Jin ⁿ  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MONASH UNIVERSITY   (Australia)

^c GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^d FUDAN UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

ⁱ GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^j SECOND MILITARY MEDICAL UNIVERSITY   (China)

^k UNIVERSITY OF TASMANIA   (Australia)

^l PEKING UNIVERSITY FIRST HOSPITAL   (China)

^m CAPITAL MEDICAL UNIVERSITY   (China)

ⁿ FUWAI HOSPITAL   (China)

more..

Author keywords

bosentan; pulmonary arterial hypertension

Indexed keywords

BOSENTAN;

ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CHINESE; CLINICAL TRIAL; COUGHING; DRUG WITHDRAWAL; EXERCISE TOLERANCE; FEMALE; FLUSHING; HUMAN; HYPOTENSION; LEUKOPENIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; TESTIS DISCOMFORT; TESTIS DISEASE; WALKING;

ADULT; ANTIHYPERTENSIVE AGENTS; CHINA; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME;

EID: 74849121144     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.09.020     Document Type: Article

References (30)

1. Hrometz S.L., and Shields K.M. Role of ambrisentan in the management of pulmonary hypertension. Ann Pharmacother 42 (2008) 1653-1659
2. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
3. Sitbon O., Badesch D.B., Channick R.N., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 124 (2003) 247-254
4. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
5. Stupi A.M., Steen V.D., Owens G.R., et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29 (1986) 515-524
6. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
7. Kawut S.M., Horn E.M., Berekashvili K.K., et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 95 (2005) 199-203
8. Jing Z.C., Xu X.Q., Han Z.Y., et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 132 (2007) 373-379
9. Carrington M., Murphy N.F., Strange G., et al. Prognostic impact of pulmonary arterial hypertension: a population-based analysis. Int J Cardiol 124 (2008) 183-187
10. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173 (2006) 1023-1030
11. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
12. Higenbottam T.W., Butt A.Y., Dinh-Xaun A.T., et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79 (1998) 175-179
13. Hsu H.H., Chen J.S., Chen R.J., et al. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. Respir Med 101 (2007) 1556-1562
14. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
15. Barst R.J., McGoon M., Torbicki A., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 40S-47S
16. Guyatt G.H., Sullivan M.J., Thompson P.J., et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 132 (1985) 919-923
17. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
18. Cella G., Vianello F., Cozzi F., et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. J Rheumatol 36 (2009) 760-767
19. D'Alto M., Vizza C.D., Romeo E., et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart 93 (2007) 621-625
20. Gatzoulis M.A., Rogers P., Li W., et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 98 (2005) 147-151
21. Ibrahim R., Granton J.T., and Mehta S. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. Can Respir J 13 (2006) 415-420
22. Provencher S., Sitbon O., Humbert M., et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27 (2006) 589-595
23. Diller G.P., Dimopoulos K., Kaya M.G., et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 93 (2007) 974-976
24. Duffels M.G., Hardziyenka M., Surie S., et al. Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension. Eur J Echocardiogr 10 (2009) 433-438
25. Mehta P.K., Simpson L., Lee E.K., et al. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects. Tex Heart Inst J 35 (2008) 256-261
26. Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
27. Gatzoulis M.A., Beghetti M., Galie N., et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 127 (2008) 27-32
28. Duffels M.G., Vis J.C., van Loon R.L., et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome. Am J Cardiol 103 (2009) 1309-1315
29. Chin K.M., Kingman M., de Lemos J.A., et al. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. Am J Cardiol 101 (2008) 1669-1672
30. Thakur M., Grossman I., McCrory D.C., et al. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 9 (2007) 826-835